Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Corporate Reputation of Pharma Companies, 2016-2017: Perspective of 86 Patient Groups With an Interest in Skin Conditions - Research and Markets

Research and Markets
Posted on: 14 Aug 17

The "The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 86 Patient Groups with an Interest in Skin Conditions" report has been added to Research and Markets' offering.

These skin results are derived from a global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).

The skin results form the opinions of 86 patient groups specialising in:

  • alopecia
  • Bechet's syndrome
  • eczema
  • scleroderma
  • psoriasis
  • vitiligo

The 86 patient groups came from 35 countries.

17 pharma companies are included in this 2016 skin analysis:

  • AbbVie
  • Amgen
  • Astrazeneca
  • Bayer
  • Boehringer Ingelheim
  • Celgene
  • Eli Lilly
  • GSK
  • Janssen
  • LEO Pharma
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche
  • Sandoz
  • Sanofi
  • Teva

How pharma is assessed for corporate reputation

Industry-wide questions:

  • How the pharma industry's corporate reputation compares with that of other healthcare industries.
  • How the pharma industry's corporate reputation has changed over the past five years.
  • How good or bad the pharma industry is at various activities of relevance to patients and patient groups.

7 indicators show the corporate reputation of individual pharma companies:

  • Patient centricity.
  • Information for patients.
  • Patient safety.
  • Usefulness of products.
  • Transparency.
  • Integrity.
  • Patient-group relationships (new for 2016).


  • In 2016, skin-conditions patient groups show higher regard for the pharma industry as a whole than patient groups from most other therapy areas. 54% of skin-conditions patient groups thought that the pharma industry had an "Excellent" or "Good" corporate reputation in 2016 (just 38% of patient groups across all therapy areas thought the same).
  • Skin-conditions patient groups ranked the biotech industry 1st among 8 healthcare-industry sectors for having an "Excellent" or "Good" corporate reputation in 2016. They ranked multinational pharma 2nd.
  • HOWEVER, skin-conditions patient groups were also, on the whole, more negative in 2016 about a number of the pharma industry's activities than patient groups from other therapy areas.
  • Only 59% of skin-conditions patient groups stated that pharma was "Excellent" or "Good" at being innovative (a score well below that of the highest, from haemophilia patient groups, of 74%).
  • Just 28% of skin-conditions patient groups stated that pharma was "Excellent" or "Good" at having integrity (again, the figure among haemophilia patient groups was 55%).


  • The company with which skin-conditions patient groups were most familiar was Pfizer (79% of respondent skin- conditions patient groups were familiar with Pfizer).


  • AbbVie ranked overall 1st in 2016 for corporate reputation among the 17 pharma companies, when judged by patient groups with an interest in skin conditions, and familiar with the company.
  • AbbVie also ranked 1st for all seven indicators of corporate reputation.
  • LEO Pharma ranked 5th out of 17 companies higher than its equivalent performance among all patient groups from different therapy areas familiar with LEO Pharma.
  • Six companies Amgen, AstraZeneca, Boehringer Ingelheim, Roche, Sanofi, and Tevawere all positioned more highly for corporate reputation in 2016 by their skin-conditions patient-group partners than by the skin-conditions patient groups which merely claimed familiarity with the companies.

For more information about this report visit

View source version on

Business Wire

Last updated on: 14/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.